Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15804177rdf:typepubmed:Citationlld:pubmed
pubmed-article:15804177lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:15804177lifeskim:mentionsumls-concept:C0031307lld:lifeskim
pubmed-article:15804177lifeskim:mentionsumls-concept:C1522604lld:lifeskim
pubmed-article:15804177lifeskim:mentionsumls-concept:C0449444lld:lifeskim
pubmed-article:15804177lifeskim:mentionsumls-concept:C1708715lld:lifeskim
pubmed-article:15804177lifeskim:mentionsumls-concept:C2346689lld:lifeskim
pubmed-article:15804177lifeskim:mentionsumls-concept:C0205373lld:lifeskim
pubmed-article:15804177pubmed:issue1lld:pubmed
pubmed-article:15804177pubmed:dateCreated2005-4-4lld:pubmed
pubmed-article:15804177pubmed:abstractTextLymph nodes are primary germination and proliferation sites for many types of pathogens. Maintaining therapeutic levels of appropriate chemotherapeutic agents in the lymph node tissue is critical for the treatment of both infection and cancer. This study was intended to develop a systemic route for loading lymph node phagocytes with drugs, using a lymph node specific nanocarrier. The latter is assembled as a 10-15 nm particle with a drug-carrying core and a phagocyte-homing poly(1-->6)-alpha-d-glucose based interface. Biokinetics and microdistribution of the model carrier were investigated in vivo. Nanocarrier accumulation in lymph nodes reached 30-35% dose/g in central lymph nodes, with deposition in various phagocytic cell populations. The latter included cells harboring inhaled microparticles translocated to lymph nodes from the lungs. In view of the nanocarrier ability to transport and release significant amounts of various drug substances, the data suggests feasibility of systemic drug loading to lymphatic phagocytes and, through drug release, to the neighboring cells.lld:pubmed
pubmed-article:15804177pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15804177pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15804177pubmed:languageenglld:pubmed
pubmed-article:15804177pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15804177pubmed:citationSubsetIMlld:pubmed
pubmed-article:15804177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15804177pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15804177pubmed:statusMEDLINElld:pubmed
pubmed-article:15804177pubmed:issn1543-8384lld:pubmed
pubmed-article:15804177pubmed:authorpubmed-author:SyedSSlld:pubmed
pubmed-article:15804177pubmed:authorpubmed-author:FischmanA JAJlld:pubmed
pubmed-article:15804177pubmed:authorpubmed-author:YimNNlld:pubmed
pubmed-article:15804177pubmed:authorpubmed-author:HillerAAlld:pubmed
pubmed-article:15804177pubmed:authorpubmed-author:PapisovM IMIlld:pubmed
pubmed-article:15804177pubmed:authorpubmed-author:KoshkinaNNlld:pubmed
pubmed-article:15804177pubmed:authorpubmed-author:YurkovetskiyA...lld:pubmed
pubmed-article:15804177pubmed:issnTypePrintlld:pubmed
pubmed-article:15804177pubmed:volume2lld:pubmed
pubmed-article:15804177pubmed:ownerNLMlld:pubmed
pubmed-article:15804177pubmed:authorsCompleteYlld:pubmed
pubmed-article:15804177pubmed:pagination47-56lld:pubmed
pubmed-article:15804177pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:meshHeadingpubmed-meshheading:15804177...lld:pubmed
pubmed-article:15804177pubmed:articleTitleA systemic route for drug loading to lymphatic phagocytes.lld:pubmed
pubmed-article:15804177pubmed:affiliationHarvard Medical School, Boston, Massachusetts 02114-2696, USA. papisov@helix.mgh.harvard.edulld:pubmed
pubmed-article:15804177pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15804177pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15804177pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15804177pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed